Citation Impact
Citing Papers
Pten Deficiency in Melanocytes Results in Resistance to Hair Graying and Susceptibility to Carcinogen-Induced Melanomagenesis
2008 StandoutNobel
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues
2007
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2009
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2011 Standout
Final Version of 2009 AJCC Melanoma Staging and Classification
2009 Standout
Similar Nucleotide Excision Repair Capacity in Melanocytes and Melanoma Cells
2010 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
2012
Advances in immunotherapy for melanoma
2016
Trametinib (GSK1120212) in the treatment of melanoma
2013
Determining cell type abundance and expression from bulk tissues with digital cytometry
2019 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
2008
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Management of Cutaneous Melanoma
2004
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
2000
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice
1988
Apoptosis
2002 Standout
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
2008 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Management of Metastatic Melanoma 2005
2006
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
2004
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Treatment of Acute Lymphoblastic Leukaemia
2007
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores
2009 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
2004
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Responses to immune checkpoint inhibitors in nonagenarians
2016
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Malignant melanoma: genetics and therapeutics in the genomic era
2006
How I treat refractory acute GVHD
2007
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
2012 Standout
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma
2017
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
2010
Reactive oxygen species: an Achilles’ heel of melanoma?
2008
Diagnosis and Treatment of mela-noma Brain Metastasis: A Literature Review
2009
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
2009
Bone metastases and breast cancer
1985
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
2005
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
2011
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
2006
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities.
1995 Standout
Works of A. Coates being referenced
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
2000
The impaired polymerization of fibrinogen Longmont (Bβ166Arg→Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers
2001
Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily × 7 every 3 weeks
2004
ADVANCED BREAST CANCER: RESPONSE TO HIGH DOSE ORAL MEDROXYPROGESTERONE ACETATE
1984